SantoSolve AS, a Olso, Norway-based biotech company that develops targeted pain therapeutics, based on a novel class of active ingredients, raised $5.5m in equity financing.
Investors include Scandinavian Venture capitalists such as Teknoinvest, InnovationsKapital and Investinor.
Founded in 2002, SantoSolve develops topical analgesic products based on non-radioactive strontium as the active substance. Its flagship product, 2PX, a pharmaceutical formulation for topical administration (applied directly on skin), is in its phase III trials.
FinSMEs
23/11/2009